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Abstract
Background: Deceleration capacity (DC) is a novel electrocardiography (ECG) parameter
characterizing the overall capacity of slowing down the heart rate. The aim of this study was to
evaluate clinical and ECG covariates of DC in patients with the first episode of ST-segment
elevation myocardial infarction (STEMI) treated with primary angioplasty.
Methods: Deceleration capacity, heart rate variability (HRV) and heart rate turbulence (HRT)
were assessed from 24-hour ECG Holter recordings in 70 patients (66 male, mean age 57 years)
with STEMI. Deceleration capacity was evaluated as continuous or dichotomized (£ 4.5 vs.
> 4.5 ms) variable.
Results: The median value of DC was 5.12 ms. Thirty patients (43%) had abnormal DC
(£ 4.5 ms). The abnormal DC was more common in female, older and hypertensive patients.
Although DC was not associated with either STEMI localization or left ventricular ejection
fraction, it was significantly correlated with mean heart rate, standard HRV indices and HRT
slope. Multivariate logistic regression showed that hypertension (OR = 3.23, 95% CI = 1.1–
–9.9, p = 0.039) and mean heart rate > 70 beats/minute (OR = 6.05, 95% CI = 2.0–18.4,
p = 0.001) were independently associated with abnormal DC.
Conclusions: Deceleration capacity in patients with the first STEMI treated with primary
angioplasty is influenced by age, gender, hypertension and heart rate, but not the location of
myocardial infarction or left ventricular ejection fraction. Correlation between DC and HRV
indices suggests that DC is related to autonomic modulation of heart rate. (Cardiol J 2009; 16,
6: 528–534)
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Introduction
For many years, ambulatory electrocardiogra-
phy (ECG) monitoring has been used in risk stra-
tification of post-infarction patients. Assessment of
various Holter-based indices gives insight into the
autonomic modulation of the cardiovascular system
and it has been proven useful in risk stratification
in post-infarction and heart failure patients [1–5].
Risk predictors based on heart rate dynamici-
ty such as heart rate variability (HRV) or heart rate
turbulence (HRT) have been extensively studied
over recent decades [6–9]. Deceleration capacity
(DC) is a new risk stratifier, characterizing heart
rate dynamics in the neighborhood of a decelera-
tion. Decreased DC was proven to be a better risk
predictor of mortality in post-infarction patients
than left ventricular ejection fraction (LVEF) and
standard deviation of normal-to-normal NN inter-
vals (SDNN) [10]. Although different studies docu-
mented that HRV and HRT are influenced by cli-
nical and ECG covariates, and suggested that these
associations should be taken into account while
using them for risk stratification purposes [7, 8, 11, 12]
the relation of DC to similar variables has not been
studied so far.
The aim of this study is to evaluate the rela-
tionship between DC and various clinical and
ECG-derived parameters in patients with the first
ST-segment elevation myocardial infarction (STEMI)
treated with the primary angioplasty.
Methods
Study population
The study population consisted of 70 consecu-
tive patients with the first STEMI and sinus rhythm
who were admitted to the hospital for percutane-
ous coronary intervention. Diagnosis of STEMI
required the following criteria: rise of cardiac bio-
markers with at least one of the following: symp-
toms of ischemia, elevation of at least 0.2 mV in men
or 0.15 mV in women in two neighboring limb leads
or V2–V3 chest leads and/or ST elevation of at least
0.1 mV in other leads, and/or new left bundle branch
block, development of pathological Q waves in the
ECG and/or imaging evidence of new loss of viable
myocardium or new regional wall motion abnormal-
ity [13]. Exclusion criteria were: non-sinus rhythm,
previous myocardial infarction and coexisting se-
vere valvular heart disease. Data on clinical cha-
racteristics and before-hospital medication was
acquired at enrollment.
Holter recordings
The 24-hour Holter ECG recordings were per-
formed between the third and fifth day after admis-
sion to evaluate mean heart rate, ventricular ar-
rhythmia, HRV, HRT, and DC. Holter recordings
were performed using Oxford Medilog System (Ox-
ford, UK). The RR intervals were exported and used
in further analysis of HRV, HRT and DC.
The HRV analysis was performed in time and
frequency domain according to ESC/NASPE guide-
lines [6]. The following time domain parameters
were calculated: SDNN, rMMSD, the square root
of the mean of the sum of the square of differences
between adjacent NN intervals, and pNN50–NN50
count divided by the total number of all NN inter-
vals. Spectral analysis included total power (TP),
low frequency power (LF for 0.04–0.15 Hz) and high
frequency power (HF for 0.15–0.4 Hz).
HRT was analyzed with the use of the original
HRTView (accessible for non-commercial purposes
from www.h-r-t.org). ECG recordings with at least
1 ventricular premature beat during the 24-hour
ECG recording were eligible for HRT analysis. In
HRT analysis two numerical descriptors: turbu-
lence onset (TO), and turbulence slope (TS) were
defined and calculated according to original meth-
od by Schmidt et al. [14]. TO and TS were defined
as abnormal according to the definition proposed by
Schmidt et al. [14]: TS £ 2.5 ms/RR and TO ≥ 0%.
We used a signal processing technique of phase
rectified signal averaging (PRSA) to process se-
quences of RR intervals obtained from Holter re-
cordings (PRSA algorithm is accessible for non-
commercial use from www.prsa.eu). The technique
provides separate characterizations of deceleration-
related modulations, quantified by DC. For compu-
tation of DC, heartbeat intervals longer than the
preceding interval are identified as anchors. Sub-
sequently segments neighboring with anchor points
are aligned around anchor points and the signal is
averaged. A detailed method of DC calculation has
been described [10, 15]. Deceleration capacity was
categorized into low (> 4.5 ms), medium (4.5–2.5 ms)
and high (£ 2.5 ms) risk categories according to the
original publication [10]. Abnormal DC was defined
as £ 4.5 ms.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Statistical analysis
Data are expressed as mean ± SD (median) for
continuous variables and as a number (percentage)
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for categorical variables. Univariate comparison of
DC values according to clinical variables was per-
formed using U-Mann-Whitney or c2 test/Fisher
exact test, where appropriate. Spearman correla-
tions were performed to evaluate the relationship
between DC and ECG parameters. Uni- and multi-
variate logistic regression analyses were used to
determine the association between clinical and
ECG variables and abnormal DC values. P value
< 0.05 was considered statistically significant. Ana-
lysis was performed with SPSS version 15 (Chica-
go, IL).
Results
Clinical characteristics of studied patients
The study population consisted of 70 patients
(55 male and 15 female) aged 36–79 years (mean
58 ± 11 years). There were 18 (26%) diabetic and
39 (57%) hypertensive patients. Twenty per cent
of patients were obese (body mass index > 30 kg/m2)
and 51% had a history of smoking. There were
39 (57%) patients with predominant ST elevation
in anterolateral leads and 31 (43%) patients with ST
elevation in inferior leads on the ECG recorded at
admission. Angioplasty was performed in all cases,
in 64 patients with stent implantation. Left ventricu-
lar ejection fraction, assessed by echocardiography
on the second or third day after revascularization,
varied from 22% to 73% (mean 53 ± 11%). Only
6% of patients presented with LVEF £ 35%. Dur-
ing Holter recordings patients were treated with
beta-blockers (94%), angiotensin converting en-
zyme (ACE) inhibitors and/or angiotensin II recep-
tor blockers (ARB; 73%), statins/fibrates (100%),
nitrates (76%) and antiplatelet therapy (100%).
Detailed characteristics of the studied population
can be seen in Table 1.
Holter recordings
During Holter recording all the patients remained
in the sinus rhythm. Ventricular premature beats
were present in 68 patients; in 7% of them frequent
ventricular premature beats > 10/h were observed;
nonsustained ventricular tachycardia was found in
five recordings (7%).
Results of HRV analysis are displayed in Ta-
ble 1. Eleven patients (16%) presented with SDNN
< 70 ms. HRT parameters were calculated in
60 patients (86%). In the remaining 14%, no ven-
tricular premature beats were found or they did not
fulfil the criteria for HRT quantification. There were
17 (28%) patients with abnormal TO, and eight
(13%) with abnormal TS. When categorizing
Table 1. Clinical and electrocardiography
characteristics of studied patients.
Parameters Studied
population
(n = 70)
Clinical variables
Age (years) 58 (55) ± 11
Age > 65 years 20 (29%)
Gender (men) 55 (79%)
Hypertension 39 (57%)
Diabetes 18 (26%)
Smoking 36 (51%)
Hyperlipidemia 44 (63%)
Body mass index > 30 kg/m2 14 (20%)
Location of myocardial infarction:
Anterolateral 39 (57%)
Inferior 31 (43%)
LVEF (%) 53 (55) ± 11
LVEF £ 30% 2 (3%)
LVEF £ 45% 13 (19%)
Systolic blood pressure [mm Hg] 133 (125) ± 23
Diastolic blood pressure [mm Hg] 82 (80) ± 14
Medication
Beta-blockers 66 (94%)
ACE inhibitors/ARB 51 (73%)
Nitrates 53 (76%)
Statins/fibrates 70 (100%)
Antiplatelets 70 (100%)
ECG variables
Mean heart rate [bpm] 71 (70) ± 10
No. of VPB 68 (7) ± 243
VPB > 10/h 5 (7%)
Heart rate variability
SDNN [ms] 99 (99) ± 30
rMSSD [ms] 38 (30) ± 24
pNN50 (%) 7.15 (3.0) ± 9.7
TPln [ms2] 7.85 (7.79) ± 1.00
LFln [ms2] 5.84 (5.89) ± 0.98
HFln [ms2] 4.95 (4.85) ± 0.99
Heart rate turbulence
TO (%) –0.92 (–1.07) ± 3.47
Abnormal TO 17 (28%)
TS [ms/RR] 11.23 (7.43) ± 12.72
Abnormal TS 8 (13%)
HRT0 36 (60%)
HRT1 23 (38%)
HRT2 1 (2%)
LVEF — left ventricular ejection fraction; ACE — angiotensin conver-
ting enzyme; ARB — angiotensin II receptor blockers; VPB — ventri-
cular premature beats; SDNN — standard deviation of all NN inter-
vals; rMSSD — root mean square of successive differences; pNN50 —
percentage of differences between adjacent NN intervals that are
> 50 ms; TPln — natural logarithm of total power; LFln — natural
logarithm of low frequency; HFln — natural logarithm of high frequ-
ency; TO — turbulence onset; TS — turbulence slope; HRT — heart
rate turbulence; HRT0 — both TO and TS normal; HRT1 — TO or TS
abnormal; HRT2 — both TO and TS abnormal
531
Joanna Lewek et al., Covariates of deceleration capacity
www.cardiologyjournal.org
patients according to original HRT criteria [14], the
HRT category 1 (TO or TS abnormal) was observed
in 24 (40%) patients and HRT category 2 was found
only in one patient (both TO and TS abnormal).
Deceleration capacity
Mean (median) value of DC was 4.94 (5.12) ±
± 2.96 ms (IQR: 3.53–6.63 ms) When categorizing
patients according to the original criteria [10],
40 (57%) patients presented with ’low risk‘ (> 4.5 ms)
DC, 23 (33%) with ’intermediate risk‘ DC and seven
(10%) with ’high risk‘ values (£ 2.5 ms). Therefore,
43% of studied patients had abnormal DC.
Clinical covariates of deceleration capacity
Deceleration capacity showed significant negative
correlation with age (r = –0.31, p = 0.011; Fig. 1).
Consequently, older patients (> 65 years) had lower
values of DC (median 4.07 vs. 5.65 ms, p = 0.030;
Table 2). Reduced DC was also observed in wom-
en (4.39 vs. 5.56 ms, p = 0.012) and patients with
hypertension (4.39 vs. 5.94 ms, p = 0.019).
Female gender, advanced age (> 65 years)
and coexisting hypertension were found to be re-
lated to abnormal values of DC (DC £ 4.5 ms) in
univariate analysis. Multivariate analysis, including
only clinical covariates, showed that female gender
was independently associated with lower values
of DC (OR = 4.2, 95% CI =1.3–4.1, p = 0.020;
Table 3).
ECG covariates of deceleration capacity
Deceleration capacity was significantly corre-
lated with mean heart rate, all HRV measures and
turbulence slope (Table 4). Patients with faster
heart rate and those with lower TS had lower DC
values (Fig. 2, 3). The analysis of the relationship
between DC and HRV parameters showed stronger
Table 2. Median values of deceleration capacity depending on clinical variables.
Clinical covariate Group Deceleration capacity p
Age (years) < 65 5.61 (5.56) ± 2.15
0.030
> 65 4.49 (4.07) ± 1.81
Gender Males 5.14 (5.56) ± 3.24
0.012
Females 4.21 (4.39) ± 1.39
LVEF £ 45% 5.53 (5.09) ± 4.77
0.906
> 45% 5.27 (5.21) ± 2.41
Diabetes Yes 3.54 (4.07) ± 4.55
0.096
No 5.42 (5.27) ± 2.0
Hypertension Yes 4.17 (4.39) ± 3.46
0.019
No 5.90 (5.94) ± 1.80
Smoking Yes 5.22 (5.18) ± 2.93
0.681
No 5.08 (4.63) ± 2.99
BMI > 30 kg/m2 4.40 (4.55) ± 3.26
0.490
< 30 kg/m2 5.07 (5.27) ± 2.9
Location of MI Anterolateral 4.42 (4.94) ± 3.39
0.255
Inferior 5.53 (5.41) ± 2.22
LVEF — left ventricular ejection fraction; BMI — body mass index; MI — myocardial infarction
Figure 1. Correlation between deceleration capacity and
age.
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correlations with spectral than with time domain
measures, with the highest correlation for LF (r = 0.66,
p < 0.001; Fig. 4). The value of DC was unaffected
by the number of premature ventricular or su-
praventricular beats.
As women have a significantly higher mean heart
rate than men (79 ± 12 vs. 69 ± 8 bpm, p < 0.001),
the mean heart rate > 70 bpm (equal to median
value of mean heart rate for the entire studied po-
pulation) was included into the multivariate logistic
regression. This analysis showed that the abnormal
DC was independently related to the presence of
hypertension (OR = 3.2, 95% CI =1.1–9.9, p = 0.039)
and the mean heart rate > 70 bpm (OR = 6.1, 95%
CI = 2.0–18.4, p = 0.001) but not female gender
(p = 0.121).
Discussion
This study shows that DC, the new risk predic-
tor of mortality after myocardial infarction, is reduced
in 43% of contemporarily treated STEMI patients and
that it is significantly correlated with mean heart rate,
several HRV indices and turbulence slope. Decelera-
tion capacity decreases with increasing heart rate and
age, it is lower in women and hypertensive patients.
As DC is positively correlated with HRV indices, its
value decreases along with HRV reduction.
Table 3. Correlations between deceleration
capacity and clinical and electrocardiography
covariates.
R* P
Age (years) –0.35 0.011
LVEF (%) 0.17 0.333
Heart rate [bpm] –0.55 < 0.001
Number of VPBs –0.06 0.638
PAC –0.13 0.268
SDNN [ms] 0.44 < 0.001
rMSSD [ms] 0.34 < 0.001
pNN50 0.49 < 0.001
TP [ms2] 0.5 < 0.001
LF [ms2] 0.66 < 0.001
HF [ms2] 0.56 < 0.001
TO (%) –0.19 0.132
TS [ms/RR] 0.37 0.003
*Spearman correlation; LVEF — left ventricular ejection fraction;
VPB — ventricular premature beats; PAC — premature atrial con-
tractions; SDNN — standard deviation of all NN intervals; rMSSD
— root mean square of successive differences; pNN50 — percenta-
ge of differences between adjacent NN intervals that are > 50 ms;
TP — total power; LF — low frequency; HF — high frequency;
TO — turbulence onset; TS — turbulence slope
Figure 2. Correlation between deceleration capacity and
mean heart rate.
Table 4. Clinical predictors of abnormal deceleration capacity in uni- and multivariate regression analyses.
Univariate Multivariate*
OR 95% CI p OR 95% CI p
Age > 65 years 1.65 0.99–1.09 0.053 1.47 0.45–4.79 0.524
Gender (female) 4.22 1.26–14.12 0.020 4.22 1.26–14.12 0.020
Diabetes 1.16 0.40–3.39 0.781
Hypertension 2.88 1.04–7.94 0.042 2.20 0.76–6.40 0.142
LVEF £ 45% 1.10 0.52–2.77 0.701
*Only covariates with significance level < 0.10 in univariate analysis were used for multivariate model; OR — odds ratio; CI — confidence interval;
LVEF — left ventricular ejection fraction
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The abnormal DC < 4.5 ms was found in 43%
of patients but only 10% of them were characte-
rized by severely reduced DC £ 2.5 ms/RR. These
numbers are comparable to those presented by
Bauer et al. [10] who analyzed data from three large
post-infarction populations. However, there are
many significant differences between patients in our
group and those described by Bauer et al. [10] Se-
verely compromised left ventricular function (LVEF
£ 30%) was present in only 3% of our patients and
in 10% of Bauer’s group  [10]. Median age of our
patients was lower than the median age of patients
in the study of Bauer et al. (55 vs. 57–64 years). The
proportion of diabetic patients is higher in our study
(26%) than in the Munich, London and Oulu groups.
Women in our study appear to differ as well, com-
paring to the age of patients from Munich (14 and
22%, respectively). Patients with previous myocar-
dial infarction were excluded from our study but not
from the study of Bauer et al. [10]. Since some of
the data used in the original study is historical, there
are significant differences in the treatment strate-
gies, such as different proportions of patients be-
ing on beta-blocker, ACE inhibitor/ARBs or statin
therapy. Further, all of our patients underwent per-
cutaneous coronary intervention, whereas this pro-
cedure was applied to 90% of patients from Munich,
24% from Oulu and was not performed on patients
from London. Altogether, these comparisons show
that some clinical characteristics are different be-
tween our patients and those presented by Bauer
et al. [10].
Bauer et al. [10] in their original report, main-
ly focused on the presentation of a new variable
(DC) with prognostic value, with no evaluation of
the relationship between DC and clinical covariates.
Our study aims to fill this gap. We have observed
that lower DC values were present in older patients,
women, and in those with hypertension. The pres-
ence of significant correlations between DC and
standard HRV indices suggest that DC is a variant
of HRV. Therefore, it is unsurprising that DC is
reduced with advancing age similarly to other HRV
parameters [16, 17]. Ageing is believed to be one
of the major determinants of decrease in heart rate
variability. Umetani et al. [17] reported that SDNN
reaches 60% of baseline values by the age of
90 years. These changes are explained by the shift
in sympathovagal balance with age with decline of
parasympathetic tone at the age of 50 years. It is
also known that women present higher resting and
24-hour mean heart rate and have lower HRV than
men [18–20] and thus reduction in DC in female
patients is not surprising either. However, in the
multivariate analysis adjusted to mean heart rate
> 70 bpm, female gender was no longer a signifi-
cant contributor to abnormal DC. In the same analy-
sis the presence of pre-hospital hypertension was
an independent and significant determinant of ab-
normal DC. Patients with hypertension present
with impaired autonomic control of the heart rate.
Figure 4. Correlation between deceleration capacity and
low frequency power of heart rate variability.
Figure 3. Correlation between deceleration capacity and
turbulence slope.
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Sympathetic stimulation and/or parasympathetic
inhibition have been considered as important con-
tributors to the development of hypertension. Se-
veral studies [21–26] have documented decreased
HRV in patients with hypertension. This is plausi-
ble evidence that the observed impairment of DC
in hypertensive STEMI patients was another mark-
er of co-existing autonomic dysfunction.
Conclusions
In conclusion, in STEMI patients treated with
coronary angioplasty during the acute phase of the
disease, the deceleration capacity is determined
mainly by pre-existing hypertension and increased
heart rate.
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